German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, ...

What was holding up a deal appeared to be the lack of affordable units, as a previous proposal called for 420. However, NYC's ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic ...